Singulair is a highly active drug that significantly improves inflammation in bronchial asthma. The drug inhibits the physiological action of cysteinyl leukotrienes, which are associated with the pathophysiology of asthma and allergic rhinitis. Any of these diagnosis may be treated by buying Singulair at online or conventional pharmacies.
Indications for use
- Prevention and long-term treatment of asthma, including the prevention of symptoms of the disease in the daytime and at night
- The treatment of bronchial asthma in patients with hypersensitivity to acetylsalicylic acid;
- The prevention of exercise-induced asthma;
- Relief of seasonal and persistent allergic rhinitis.
Dosage
- It is prescribed for oral application once a day, regardless of the meal.
- For the treatment of asthma, the drug should be taken in the evening.
- When treating allergic rhinitis, the drug can be taken at any time of the day. Patients with asthma and allergic rhinitis should take one tablet once a day in the evening.
- Adults and teenagers from the age of 15: 1 tablet, film coated (10 mg), once a day.
- Chewable tablets can be swallowed whole or chewed before swallowing.
- Children aged 6 to 14 years: one chewable tablet – 5 mg once a day. Dose selection for this age group is not required.
- Children over 15 years old and adults: 10 mg per day.
General recommendations
The therapeutic drug effect on the symptoms, reflecting the course of bronchial asthma, manifests itself during the first day. The patient should continue to take the drug in the period to achieve control of symptoms of bronchial asthma and in the period of disease exacerbation.
Special patient groups
For elderly patients, patients with renal insufficiency, with mild or moderately impaired hepatic function, dose adjustment is not required. The drug dose is the same for female and male patients.
Application simultaneously with other types of bronchial asthma treatment
The drug can be added to the treatment with bronchodilators and inhaled glucocorticosteroids (GCS).
Side effects
Singulair side effects are usually mild which, as a rule, do not require drug discontinuation.
- Nervous system disorders: headache, dizziness, drowsiness, paresthesia/hypesthesia, convulsions.
- Heart dysfunctions: palpitations.
- Dysfunctions of the respiratory system, organs of the chest and mediastinum: nasal bleeding, pulmonary eosinophilia.
- Mental disorders: agitation, including aggressive behavior or hostility, anxiety, depression, disorientation, attention disorder, pathological dreams, hallucinations, insomnia, memory disorders, psychomotor activity (including irritability, anxiety and tremor), somnambulism, suicidal thoughts and behavior.
- Disorders of the gastrointestinal tract: diarrhea, dyspepsia, nausea, vomiting, pancreatitis, abdominal pain, thirst.
- Liver and biliary tract disorders: increased activity of alanine aminotransferase (ALT) and aspartate aminotransferase (ACT), hepatitis (including cholestatic, hepatocellular and mixed liver damage).
- Disorders of the musculoskeletal and connective tissues: arthralgia, myalgia, muscle cramps.
- Disorders of the blood and lymphatic system: an increased tendency to bleeding, thrombocytopenia.
- Violations of the skin and subcutaneous tissues: a tendency to the formation of hematomas, erythema nodosum, erythema multiforme, pruritus, rash, urticaria, angioedema.
- Immune system disorders: hypersensitivity reactions, including anaphylaxis, eosinophilic infiltration of the liver.
- Infectious and parasitic diseases: upper respiratory tract infections.
- General disorders and disorders at the injection site: asthenia (weakness)/fatigue, edema, pyrexia.
Overdose
Symptoms
Data on overdose symptoms when taking this drug at a dose of more than 200 mg/day for 22 weeks and at a dose of 900 mg/day for one week, was not detected.
There have been cases of acute overdose (when taking at least 1000 mg/day) during the post-registration period and during clinical trials in adults and children. Clinical and laboratory data indicated the comparability of the safety profiles of this drug in children, adults and elderly patients.
The most frequent side effects were thirst, drowsiness, vomiting, agitation, headache, abdominal pain, mydriasis. These side effects are consistent with the security profile of Singulair.
Treatment
Treatment for acute overdose is symptomatic. No information is available on the specific treatment of overdose. There is no evidence of the effectiveness of peritoneal dialysis or hemodialysis.
Interactions
According to clinical studies, Singulair in recommended doses does not have a clinically significant effect on the pharmacokinetic profile of drugs such as theophylline, prednisone, prednisolone, combined oral contraceptives (norethisterone 1 mg and ethinyl estradiol 35 µg), terfenadine, digoxin and warfarin.
The use of these asthma pills as a concomitant drug in clinical studies, together with a wide range of commonly prescribed drugs (thyroid hormones, NSAIDs, benzodiazepines, decongestants) did not lead to the development of clinically significant drug interactions. These special clinical studies are not available.
Pregnancy and lactation
There were no clinical trials of Singulair involving pregnant women. This remedy should be used during pregnancy and lactation only if the expected benefit to the mother outweighs the potential risk to the fetus or baby. During the post-registration use, the development of congenital limb defects in newborns whose mothers took this drug during pregnancy was reported. Most of these women also took other drugs for the treatment of bronchial asthma during pregnancy. The causal relationship between taking Singulair and the development of congenital defects of the limbs has not been established.
It is not known whether this is excreted in breast milk. Since many drugs are excreted in breast milk, it is necessary to take this into account when prescribing this drug for asthma for breastfeeding women.